| Revenue growth | 23.1% YoY consolidated growth. |
|---|---|
| Margins | EBITDA margin at 20.03%; PAT margin at 11.8%. |
| Demand visibility | Strong, driven by first-to-market respiratory launches and innovation platforms. |
| Management confidence | High, citing broad-based growth and strong execution across key markets. |
Growth
Revenue grew 23.1% YoY; EBITDA reached Rs. 8,048 million with a 20.03% margin. PAT stood at Rs. 4,828 million.
Outlook
Targets sustainable growth through differentiated specialty launches, oncology portfolio progress, and IGI's pipeline expansion.
Risks
Risks include global macroeconomic shifts, currency/interest rate volatility, and increasing competition in the pharmaceutical industry.
Investor Presentation filed with BSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,282.30
- Market cap
- ₹64,412 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 35.8×Sector 47.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.